| Document and Entity Information | Jun. 20, 2024 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jun. 20, 2024 |
| Entity Registrant Name | Omega Therapeutics, Inc. |
| Entity Central Index Key | 0001850838 |
| Entity Emerging Growth Company | true |
| Securities Act File Number | 001-40657 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 81-3247585 |
| Entity Address, Address Line One | 140 First Street |
| Entity Address, Address Line Two | Suite 501 |
| Entity Address, City or Town | Cambridge |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02141 |
| City Area Code | 617 |
| Local Phone Number | 949-4360 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Ex Transition Period | false |
| Title of 12(b) Security | Common Stock, $0.001 par value per share |
| Trading Symbol | OMGA |
| Security Exchange Name | NASDAQ |
| Current Fiscal Year End Date | --12-31 |
